Contact
searchSearch
HMP Global
Login

News

Rebecca Porter, MD, PhD
Videos
Rethinking Treatment Strategies in Recurrent Ovarian Cancer
03/17/2026
Rebecca Porter, MD, PhD
Rebecca Porter, MD, PhD, discusses whether treatment paradigms for recurrent ovarian cancer should evolve beyond traditional regulatory standards.
Rebecca Porter, MD, PhD, discusses whether treatment paradigms for recurrent ovarian cancer should evolve beyond traditional regulatory standards.
Rebecca Porter, MD, PhD,...
03/17/2026
Oncology
FDA Approval
FDA Approves Pembrolizumab-Based Regimens for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
02/10/2026
Emily Estrada
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA approved pembrolizumab and pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for patients with PD-L1-positive, platinum-resistant epithelial ovarian,...
On February 10, 2026, the FDA...
02/10/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology
FDA Approval
FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer
09/10/2025
Allison Casey
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for...
09/10/2025
Oncology
News
Alpelisib Plus Olaparib Fails to Improve Outcomes For Platinum-Resistant/Platinum-Refractory High-Grade Serous Ovarian Cancer
08/19/2025
Stephanie Holland
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis...
08/19/2025
Oncology
FDA Approval
FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
05/08/2025
Stephanie Holland
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the...
05/08/2025
Oncology
News
TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
04/29/2025
Stephanie Holland
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the...
04/29/2025
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves PFS for Patients With Platinum-Resistant Ovarian Cancer
04/04/2025
Stephanie Holland
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA...
04/04/2025
Oncology

Recent News

FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use